Johnson Johnson AbbVie: Paths to Pharma Dominance
Johnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Explore how volatility affects retirees in index funds and what tactics—like rebalancing and withdrawal rules—can help manage risk.
23,261 articlesJohnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Anthropic and Airbnb are placing big bets on New York City, expanding footprints and hiring aggressively while critic...
Meta's AI model projects a substantial rally for gold and silver by end-2026, framing both as twin bets on a shared m...
Kymera’s CEO recently monetized a sizable stake after a strong run. This article unpacks the insider sale, what kymer...
As AI investment surges, the real cash flow winners are the hardware and infrastructure suppliers. Analysts say forge...
As global markets evolve, two popular international ETFs—IXUS and SCHE—offer different paths to diversification. This...
A cooler June CPI print sparked a risk-on bid in semiconductors, with AMD surging and Intel climbing as investors bet...
SoftBank CEO Masayoshi Son says global AI demand will need roughly $5 trillion each year to scale infrastructure, arg...
On Tuesday, Broadcom shifted higher as investors rotated into hardware names and welcomed a positive analyst update. ...
Analysts publish an eyebrow-raising spacex’s $800 price target, implying a potential trillion-dollar leap in value an...
Jefferies positions Amazon as the leading Mag 7 stock headed into earnings, underscoring AWS momentum, Prime Day stre...
Alphabet faces a pivotal year as AI monetization expands and cloud momentum compounds. Traders watch how capital spen...